ArticleCancer science2012

Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma.

Takuji Okusaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.